Psychiatry should not become hostage to placebo: An alternative interpretation of antidepressant-placebo differences in the treatment response in depression

European Neuropsychopharmacology

Volumn 22, Issue 11, 2012, Pages 782-786

  Rihmer, Zoltan ^a   Dome, Peter ^a   Baldwin, David S ^b   Gonda, Xenia ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

^b UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Antidepressant; Antidepressant drug response; Antidepressant efficacy; Placebo

Indexed keywords

ANTIDEPRESSANT AGENT; PLACEBO;

ARTICLE; CALCULATION; DRUG EFFICACY; HOSTAGE; HUMAN; MAJOR DEPRESSION; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; HUMANS; PLACEBO EFFECT; PLACEBOS; PSYCHIATRY; PSYCHOPHARMACOLOGY; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84867495545     PISSN: 0924977X     EISSN: 18737862     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2012.03.002     Document Type: Article

References (29)

1. Adam D., Kasper S., Moller H.J., Singer E.A. Placebo-controlled trials in major depression are necessary and ethically justifiable: how to improve the communication between researchers and ethical committees. Eur. Arch. Psychiatry Clin. Neurosci. 2005, 255:258-260.
2. Baldwin D., Broich K., Fritze J., Kasper S., Westenberg H., Moller H.J. Placebo-controlled studies in depression: necessary, ethical and feasible. Eur. Arch. Psychiatry Clin. Neurosci. 2003, 253:22-28.
3. Brown G.W. Social roles, context and evolution in the origins of depression. J. Health Soc. Behav. 2002, 43:255-276.
4. Eriksson E. Has the demand for evidence in psychiatry become counterproductive?. Int. J. Psychiatry Clin. Pract. 2011, 15:3-4.
5. Fountoulakis, K.N., Moller, H.J. Antidepressant drugs and the response in the placebo group: the real problem lies in our understanding of the issue. J. Psychopharmacol, in press.
6. Gueorguieva R., Mallinckrodt C., Krystal J.H. Trajectories of depression severity in clinical trials of duloxetine: insights into antidepressant and placebo responses. Arch. Gen. Psychiatry 2011, 68:1227-1237.
7. Hankin B.L., Oppenheimer C., Jenness J., Barrocas A., Shapero B.G., Goldband J. Developmental origins of cognitive vulnerabilities to depression: review of processes contributing to stability and change across time. J. Clin. Psychol. 2009, 65:1327-1338.
8. Hegerl U., Mergl R. The clinical significance of antidepressant treatment effects cannot be derived from placebo-verum response differences. J. Psychopharmacol. 2010, 24:445-448.
9. Holzel L., Harter M., Reese C., Kriston L. Risk factors for chronic depression-a systematic review. J. Affective Disord. 2011, 129:1-13.
10. Isacsson, G., Adler, M. Randomized clinical trials underestimate the efficacy of antidepressants in less severe depression. Acta Psychiatr. Scand., http://dx.doi.org/10.1111/j.1600-0447.2011.01815.x, in press.
11. Laporte J.R., Figueras A. Placebo effects in psychiatry. Lancet 1994, 344:1206-1209.
12. Leichsenring F., Leibing E., Kruse J., New A.S., Leweke F. Borderline personality disorder. Lancet 2011, 377:74-84.
13. Montgomery S. Sunset on new psychotropics in Europe. Int. J. Psychiatry Clin. Pract. 2011, 15:4.
14. Nutt D.J., Malizia A.L. Why does the world have such a 'down' on antidepressants?. J. Psychopharmacol. 2008, 22:223-226.
15. Paykel E.S., Brugha T., Fryers T. Size and burden of depressive disorders in Europe. Eur. Neuropsychopharmacol. 2005, 15:411-423.
16. Pedersen A.G. Economic barriers to developing new treatments. Int. J. Psychiatry Clin. Pract. 2011, 15:4.
17. Pompili M., Girardi P., Ruberto A., Tatarelli R. Suicide in borderline personality disorder: A meta-analysis. Nordic J. Psychiatry 2005, 59:319-324.
18. Quitkin F.M. Placebos, drug effects, and study design: a clinician's guide. Am. J. Psychiatry 1999, 156:829-836.
19. Rihmer Z. Drug-placebo difference: in antidepressant drug trials could be 50% greater than previously believed. Neuropsychopharmacol. Hung. 2007, 9:35-37.
20. Rihmer Z. Suicide risk in mood disorders. Curr. Opin. Psychiatry 2007, 20:17-22.
21. Rihmer Z., Angst J. Mood disorders-epidemiology. Kaplan and Sadock's Comprehensive Textbook of Psychiatry 2009, 1645-1653. Lippincott, Williams and Wilkins, Philadelphia. B.J. Sadock, V.A. Sadock, P. Ruiz (Eds.).
22. Rihmer Z., Gonda X. Is drug-placebo difference in short-term antidepressant drug trials on unipolar major depression much greater than previously believed?. J. Affective Disord. 2008, 108:195-198.
23. Rihmer Z., Gonda X., Dome P., Erdos P., Ormos M., Pani L. Novel approaches to drug-placebo difference calculation: evidence from short-term antidepressant drug-trials. Hum. Psychopharmacol. 2011, 26:307-312.
24. Rihmer Z., Gonda X., Faludi G., Fountoulakis K.N. Positive antidepressant pharmacotherapy in reducing suicide morbidity and mortality in unipolar depression. Eur. Psychiat. Rev. 2008, 2:59-62.
25. Rimlinger B. Depression and personality disorders: mutual influences. Encephale 2010, 36:s123-s126.
26. Scott J., Dickey B. Global burden of depression: the intersection of culture and medicine. Br. J. Psychiatry 2003, 183:92-94.
27. Walsh B.T., Seidman S.N., Sysko R., Gould M. Placebo response in studies of major depression: variable, substantial, and growing. JAMA: J. Am. Med. Assoc. 2002, 287:1840-1847.
28. *D report. Am. J. Psychiatry 2009, 166:599-607.
29. Zetin M., Hoepner C.T. Relevance of exclusion criteria in antidepressant clinical trials: a replication study. J. Clin. Psychopharmacol. 2007, 27:295-301.